EU Pharma Loses €10.2bn, 38,000 Jobs To Counterfeits As “Massive” Track & Trace Obligations Approach
Executive Summary
As a new report reveals that 4.4% of legitimate sales of drugs are lost each year in the EU due to counterfeiting, drug companies are being warned not to underestimate how much work they will need to do to comply with new track and trace rules.
You may also be interested in...
Ireland Chooses "Blueprint" System To Link Into Future EU Product Verification Network
New Irish system will link into the European verification network that is being set up to detect incidents of falsified medicines entering the supply chain using a "unique identifier" on most packs of prescription drugs, starting from February 2019.
EU Pharma Has Three Years To Comply With New Safety Feature Rules
The new EU rules on the safety feature to be attached to almost all prescription medicines have finally been published, and once they kick in products will have to carry a 'unique identifier' in the form of a 2D bar code on the pack that will allow its authenticity to be verified1.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.